Treatment of iron deficiency anemia in women with different comorbidities Haematological Disorders Iron deficiency anaemia, unspecified
Conditions
Interventions
Female patients were enrolled for the study and a well-informed written consent was taken from all the patients before starting the therapy. Participants were randomly allocated in a 1:1 ratio using S
Sponsors
University of Kashmir
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: All patients diagnosed with IDA admitted/or present for consultation in the Obstetrics and Gynecology ward of SKIMS Medical College and Hospital, Bemina, Srinagar were enrolled during the study period
Exclusion criteria
Exclusion criteria: 1. Patients with uncontrolled hypertension 2. Patients with impaired renal function 3. Patients with impaired liver function 4. Patients with heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at baseline, 2 and 4 weeks: 1. The effectiveness and safety of FCM with respect to IS in achieving the target levels of laboratory biomarkers such as Hb, mean corpuscular volume (MCV), serum iron (SI), serum ferritin (SF), transferrin saturation (TS%), total iron binding capacity (TIBC) levels as prescribed under standard guidelines 2. Drug-related problems in patients on FCM or IS 3. The time required to attain normal laboratory biomarker levels | — |
Secondary
| Measure | Time frame |
|---|---|
| Health-related quality of life (HRQOL), measured using the Medical Outcomes Study Short Form 36 (SF-36) at baseline, 2 and 4 weeks | — |
Countries
India
Outcome results
None listed